中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
22期
10192-10196
,共5页
Meta分析%康艾注射液%全身化疗%恶性肿瘤
Meta分析%康艾註射液%全身化療%噁性腫瘤
Meta분석%강애주사액%전신화료%악성종류
Meta-analysis%Kang Ai Injection%Systemic chemotherapy%Malignant tumor
目的：从循证医学的角度系统评价康艾注射液联合全身化疗治疗中、晚期恶性肿瘤的近期疗效和安全性，为临床应用提供依据。方法计算机检索中国期刊全文数据库、PubMed、万方数据库中关于康艾注射液联合全身化疗方案治疗恶性肿瘤的临床随机对照试验（RCT）文献，依据Cochrane评价手册评价文献质量，提交数据进行荟萃分析。结果近期疗效比较RR值为1.25，95%可信区间为1.15～1.36， P＜0.01；Karnofsky评分改善情况比较RR值为1.82，95%可信区间为1.66～1.99，P＜0.01；在安全性方面，使用康艾注射液联合全身化疗时Ⅱ度和Ⅱ度以上不良反应发生率较单用化疗方案更低，其中消化道反应比较RR值为0.68，95%可信区间为0.58～0.79，P＜0.01；骨髓抑制反应比较RR值为0.60，95%可信区间为0.55～0.65， P＜0.01。结论康艾注射液联合全身化疗方案治疗恶性肿瘤可能取得较单纯全身化疗更好的疗效和更低的不良反应发生率。
目的：從循證醫學的角度繫統評價康艾註射液聯閤全身化療治療中、晚期噁性腫瘤的近期療效和安全性，為臨床應用提供依據。方法計算機檢索中國期刊全文數據庫、PubMed、萬方數據庫中關于康艾註射液聯閤全身化療方案治療噁性腫瘤的臨床隨機對照試驗（RCT）文獻，依據Cochrane評價手冊評價文獻質量，提交數據進行薈萃分析。結果近期療效比較RR值為1.25，95%可信區間為1.15～1.36， P＜0.01；Karnofsky評分改善情況比較RR值為1.82，95%可信區間為1.66～1.99，P＜0.01；在安全性方麵，使用康艾註射液聯閤全身化療時Ⅱ度和Ⅱ度以上不良反應髮生率較單用化療方案更低，其中消化道反應比較RR值為0.68，95%可信區間為0.58～0.79，P＜0.01；骨髓抑製反應比較RR值為0.60，95%可信區間為0.55～0.65， P＜0.01。結論康艾註射液聯閤全身化療方案治療噁性腫瘤可能取得較單純全身化療更好的療效和更低的不良反應髮生率。
목적：종순증의학적각도계통평개강애주사액연합전신화료치료중、만기악성종류적근기료효화안전성，위림상응용제공의거。방법계산궤검색중국기간전문수거고、PubMed、만방수거고중관우강애주사액연합전신화료방안치료악성종류적림상수궤대조시험（RCT）문헌，의거Cochrane평개수책평개문헌질량，제교수거진행회췌분석。결과근기료효비교RR치위1.25，95%가신구간위1.15～1.36， P＜0.01；Karnofsky평분개선정황비교RR치위1.82，95%가신구간위1.66～1.99，P＜0.01；재안전성방면，사용강애주사액연합전신화료시Ⅱ도화Ⅱ도이상불량반응발생솔교단용화료방안경저，기중소화도반응비교RR치위0.68，95%가신구간위0.58～0.79，P＜0.01；골수억제반응비교RR치위0.60，95%가신구간위0.55～0.65， P＜0.01。결론강애주사액연합전신화료방안치료악성종류가능취득교단순전신화료경호적료효화경저적불량반응발생솔。
Objective To systematically appraise recent efficacy and safety of Kang Ai Injection unite with systemic chemotherapy for treatment of medium and late malignant tumor, thus to provide an evidence-based guidance for clinical practice. Methods Reports of Kang Ai Injection unite with systemic chemotherapy for treatment of medium and late malignant tumor were searched in Chinese Journal Full-text Database and Chinese Biomedical Literature Database and PubMed and WanFang data by computer, On the basis of the Cochrane quality evaluation manual evaluation literature, meta-analysis to submit data. Results The risk ratio(RR) and 95%confidence interval (95%CI) of the comparison of the improvement on recent efficacy were 1.25(1.15-1.36), P<0.01, and the RR and 95%CI of the improvement on Karnofsky score were 1.82(1.66-1.1.99), P<0.01. The RR and 95% CI on the myelo-suppression of Ⅱ degree or above and digestive reaction were 0.60(0.55-0.65), P<0.01 and 0.68(0.58-0.79), P<0.01. Conclusion The combination of Kang Ai Injection unite with systemic chemotherapy may have better effectively and safety for Medium and late malignant tumor than the regular systemic chemotherapy had.
